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Abstract
Background: The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid
arthritis (RA). Protein levels of IFNα have not been measured in RA and it is unknown whether they associate with
clinical characteristics or treatment effect.
Methods: Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone,
certolizumab-pegol, abatacept, or tocilizumab. Plasma IFNα protein levels were determined by single molecular
array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors
including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and
patient global assessment.
Results: IFNα protein positivity was found in 26% of the patients, and of these, 92% were double-positive for
rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFNα protein levels were reduced 24 weeks
after treatment initiation, and the absolute change was similar irrespective of treatment. IFNα protein positivity was
associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization.
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Conclusion: IFNα protein positivity is present in a subgroup of patients with early RA and associates with double-
positivity for autoantibodies but not with disease activity. Pre-treatment IFNα positivity did not predict remission in
any of the treatment arms, suggesting that the IFNα system is distinct from the pathways of TNF, IL-6, and T-cell
activation in early RA.
A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011,
https://clinicaltrials.gov/ct2/show/NCT01491815.
Introduction
Rheumatoid arthritis (RA) is a chronic disease character-
ized by joint inflammation, which if untreated may lead
to progressive bone destruction. Genetic and environ-
mental factors contribute to the predisposition towards
disease development, including smoking and genes of
the type I interferon (IFN) pathway [1–3]. The majority
of patients with RA have autoantibodies against the Fc
portion of IgG (rheumatoid factor (RF)) and/or citrulli-
nated peptides (ACPA). Two studies have shown that
ACPA positivity is associated with elevated expression of
type I IFN responsive genes (IRG) in RA [4, 5], while
others have reported that these factors are unrelated [6,
7]. Whether RF or ACPA are associated with IFNα pro-
tein is unknown.
The majority of IFNα is produced by plasmacytoid
dendritic cells following their recognition of microbial
nucleic acids and immune complexes. Binding to the
type I IFN receptor leads to upregulation of genes in-
volved in immune processes including restriction of viral
replication and enhancement of B cell responses [8]. A
persistent upregulation of IRG, the type I IFN signature,
is evident in several autoimmune diseases including sys-
temic lupus erythematosus (SLE) and RA [9]. In RA, the
expression of IRG is upregulated in peripheral blood
compared to controls [10] and was suggested to associ-
ate with disease activity [11] and predict treatment re-
sponse to tumor necrosis factor inhibitors (TNFi) [12–
14], interleukin-6 receptor inhibitors (IL-6Ri) [15], and
B-cell depletion therapy [16–19]. However, the stimula-
tion of IRG expression is not specific for IFNα and
which genes to include is not standardized. Since func-
tional bioassays are not specific for IFNα, and traditional
ELISAs are insufficiently sensitive, a reliable method to
measure IFNα protein has been lacking. Recently, a
digital ELISA based on single molecular array (Simoa)
was developed that enables direct quantification of IFNα
at attomolar levels [20]. In SLE, IFNα protein associated
with disease activity and predicted the duration of remis-
sion [21], but protein levels of IFNα have previously nei-
ther been reliably measured in RA nor related to clinical
characteristics or treatment effect.
Early and effective medical treatment improves well-
being and prognosis in RA. Current European and US
guidelines advocate initiating treatment with methotrex-
ate (MTX) or other conventional synthetic disease-
modifying anti-rheumatic drug (DMARD) [22, 23]. If the
therapeutic effect is insufficient, another conventional,
biologic, or targeted synthetic DMARD may be added.
In the NORD-STAR cohort, active conventional treat-
ment and biologic treatment with certolizumab-pegol,
abatacept, and tocilizumab were compared head-to-head
[24]. All four treatments achieved high remission rates
on a group level. At the individual level, it may be pos-
sible to predict treatment effect using biomarkers, but
specific biomarkers that inform on the effect of different
treatment strategies in early RA are lacking.
We used plasma samples from the Swedish patients in
the NORD-STAR cohort to explore whether IFNα pro-
tein positivity is present in patients with early untreated
RA, whether levels of IFNα change after treatment with
conventional and biologic treatment strategies, and




The study population consisted of 347 Swedish patients
included in the NORD-STAR trial, a multinational phase
four, investigator-initiated, randomized observer-blinded
clinical trial of 812 patients with early untreated RA
[24]. All patients fulfilled the American College of
Rheumatology (ACR) and European League Against
Rheumatism (EULAR) 2010 criteria. Patients were
assessed for eligibility during 2012–2018. All patients
were of age 18 or above, had a symptom duration of
fewer than 24months, and at least two (of 66) swollen
and two (of 68) tender joints. All patients had to be RF
and/or ACPA positive or have a C-reactive protein
(CRP) of at least 10 mg/L. All patients had moderate to
severe disease activity score (DAS28-CRP ≥ 3.2) and all
were DMARD naïve. Active infection or any major epi-
sode of infection requiring hospitalization within 4 weeks
of screening constituted exclusion criteria. All partici-
pants signed a written informed consent and the study
was approved by the regional ethics board in Stockholm
(d.nr. 2011/2069-31/4 and amendment 2019-05705).
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Intervention
Details of the study protocol and data regarding clinical
outcome at week 24 in the full NORD-STAR cohort are
published [24, 25]. In brief, Swedish patients were ran-
domized 1:1:1:1 stratified by ACPA and sex to MTX es-
calated to 25mg/week with folic acid supplementation
combined with one of the following: arm 1, active con-
ventional treatment (oral prednisone tapered from 20 to
5 mg/day in 9 weeks); arm 2, TNFi (certolizumab-pegol,
200 mg subcutaneously every other week, loading dose
400 mg at weeks 0, 2, and 4); arm 3, cytotoxic T-
lymphocyte-associated molecule-4 immunoglobulin
(CTLA-4Ig, abatacept, 125 mg subcutaneously every
week); or arm 4, IL-6Ri (tocilizumab, 8 mg/kg intraven-
ously every 4 weeks or 162 mg subcutaneously every
week). There was no difference between the intention-
to-treat and the per-protocol treatment arm. Oral ste-
roids were not allowed for patients who received a bio-
logical DMARD (arm 2–4). Intra-articular corticosteroid
injections were allowed on demand up to week 20 in
arm 1 and until week 12 in arm 2–4. If an oral dose of
25 mg/week MTX was not tolerated, the dose was re-
duced or changed to subcutaneously administered MTX;
if MTX was still not tolerated, it was replaced with leflu-
nomide or azathioprine, or monotherapy for patients on
biologic medication. None of the patients was treated
with hydroxychloroquine.
Clinical evaluation
The primary clinical endpoint was remission according
to the clinical disease activity index (CDAI ≤ 2.8) at
week 24. In addition, disease activity was evaluated on
day 1 before the start of treatment and 24 weeks after
treatment initiation with the following parameters: CRP,
erythrocyte sedimentation rate (ESR), DAS28-ESR and
DAS28-CRP, swollen joint count in 66 joints (SJC66),
tender joint count in 68 joints (TJC68), and patient glo-
bal assessment (PGA). Positivity for ACPA and RF was
determined according to cut-off levels at the local
laboratories.
Quantification of IFNα in plasma
Plasma was kept frozen until analysis. Plasma IFNα pro-
tein concentration was measured with Simoa on an HD-
1 Analyzer (Quanterix, Billerica, MA). The analysis was
performed blinded to patient characteristics. The Simoa
assay contained an inhibitor for RF and heterophilic
antibodies in order to prevent false-positive results.
Values below the detection limit were assigned the low-
est limit of detection (LLOD, 70 fg/mL). Within-run and
between-run coefficients of variation (CVs) for the
Simoa assay were 9.8% and 7.3% at 1.9 pg/mL and 8.1%
and 7.3% at 10.6 pg/mL. The assay was not controlled
for concentrations lower than 1.9 pg/mL. IFNα protein
positivity was defined as an IFNα level ≥ 136 fg/mL,
based on three standard deviations above mean level for
healthy blood donors, measured using the same method
[21]. IFNα protein levels could not be obtained due to a
technical error in one sample collected at baseline and
one sample collected at 24 weeks.
Statistics
Mann-Whitney U-test, Wilcoxon matched-pairs signed
rank test, Kruskal-Wallis test followed by Dunn’s mul-
tiple comparison test (GraphPad Prism software v9.02,
La Jolla, CA), and Fisher’s exact test (IBM SPSS Statistics
v27, Armonk, NY) were used as described in the respect-
ive figure legends. For analysis of autoantibody status in
relation to IFNα, after Fisher’s exact test, a post hoc
step-down Bonferroni-Holm correction for multiple test-
ing was performed. Multivariable logistic regression was
used to identify factors independently associated with
IFNα protein positivity and identify whether IFNα pro-
tein positivity was independently associated with remis-
sion at week 24 (GraphPad Prism software). A p-value of
< 0.05 was considered statistically significant (*P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001).
Results
IFNα protein positivity is present in a subgroup of
untreated early RA patients
Baseline demographic and clinical characteristics of the
347 patients with untreated early RA in each treatment
arm are shown in Table 1. There were no significant dif-
ferences in baseline characteristics between the four
treatment arms. Of the 346 patients with data for plasma
IFNα protein levels at baseline, 26% (n = 91) were IFNα-
positive, with similar proportions in the four treatment
arms, i.e., methotrexate in combination with either pred-
nisone (27%, n = 23), TNFi (22%, n = 19), CTLA-4Ig
(29%, n = 27), or IL-6Ri (27%, n = 22) (Fig. 1).
IFNα protein positivity is associated with double-
positivity for RF and ACPA
To determine the demographic and clinical characteris-
tics of the IFNα protein-positive subgroup, we compared
patients who were positive or negative for IFNα protein
at baseline. IFNα protein positivity was associated with
double-positivity for RF and ACPA, and of IFNα-
positive patients, 92% were double-positive for RF and
ACPA compared to 57% of IFNα-negative patients. In
contrast, only 3% of IFNα-positive patients were double-
negative, and only 4% were positive for either RF or
ACPA compared to 13% and 29% of IFNα-negative pa-
tients, respectively (Table 2 and Additional Figure 1).
Baseline IFNα protein positivity was not associated with
age, sex, or BMI, and not with disease activity measures
at baseline or 24 weeks after treatment initiation. Similar
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results were obtained when LLOD was used as a cut-off
for IFNα positivity (Additional Table 1). When double-
positive patients were divided into IFNα-positive and
IFNα-negative patients, no significant differences in
CDAI day 1 or week 24 (p = 0.07 and p = 0.45 respect-
ively) or DAS28-ESR day 1 or week 24 (p = 0.28 and p =
0.79 respectively) were found.
To evaluate whether the association between IFNα
and double-positivity for RF and ACPA was due to
demographic or clinical characteristics, multivari-
able logistic regression analysis was performed
(Table 3). Double-positivity for RF and ACPA was
associated with IFNα protein positivity and in-
creased the odds ratio of IFNα protein positivity
ninefold at baseline and fivefold at week 24 when
adjusting for current smoking, CDAI, and CRP.
Current smoking independently doubled the odds
ratio of IFNα protein positivity at week 24 but nei-
ther CDAI nor CRP affected the odds ratio. Taken
together, baseline IFNα protein positivity was inde-
pendently associated with double-positivity for RF
and ACPA and smoking but not with disease activ-
ity in early RA.
Table 1 Baseline characteristics of untreated patients with early RA in the four treatment arms
N = 347 MTX + prednisone (n = 85) MTX + TNFi (n = 87) MTX + CTLA-4Ig (n = 92) MTX + IL-6Ri (n = 83) P-value
Age, yearsa 62 (21–81) 58 (21–79) 58 (18–82) 53 (25–79) 0.29
Female sexb 58 (68%) 58 (67%) 62 (67%) 57 (69%) 0.99
BMI, kg/m2a 26 (18–43) 25 (19–37) 26 (18–38) 25 (20–43) 0.11
Current smokerb 12 (14%) 20 (23%) 18 (20%) 22 (27%) 0.22
Autoantibody status 0.55
RF-ACPA-b 11 (13%) 10 (11%) 11 (12%) 4 (5%) –
RF+ACPA-b 5 (6%) 6 (7%) 5 (5%) 9 (11%) –
RF-ACPA+b 11 (13%) 14 (16%) 12 (13%) 17 (20%) –
RF+ACPA+b 57 (67%) 57 (66%) 64 (70%) 53 (64%) –
Symptom duration, daysa,c 142 (25–813) 144 (41–702) 170 (37–731) 170 (37–691) 0.29
CDAIa 30.7 (7.8–62.8) 27.9 (8.1–68.7) 29.5 (14–68.4) 26.8 (8.4–55.2) 0.33
DAS28-CRPa 5.2 (2.6–7.7) 5.1 (2.2–8.3) 5.1 (3.3–7.6) 5.0 (2.7–7.3) 0.21
DAS28-ESRa 5.6 (3.6–8.2) 5.6 (2.7–8.7) 5.5 (3.7–8.1) 5.3 (2.6–7.9) 0.23
SJC-66a 13 (2–42) 12 (2–34) 11 (2–41) 10 (1–27) 0.10
TJC-68a 15 (2–47) 15 (1–47) 14 (0–62) 13 (0–47) 0.55
CRP, mg/ a 16 (0.5–216) 14 (0.5–180) 11 (0.3–146) 8.4 (0.3–82) 0.19
ESR, mm/ha 31 (4-108) 32 (4–98) 28 (4–115) 24 (2–84) 0.14
PGA, mma 58 (2–87) 57 (13–100) 61 (19–100) 59 (9–100) 0.18
Missing data from one patient regarding BMI, RF, IFN day 1, IFN week 24, CDAI week 24, PGA week 24, and ESR week 24; from two patients regarding CRP day 1
and DAS28-ESR week 24; from three patients regarding CRP week 24; from four patients regarding CDAI day 1 and DAS28-CRP week 24; and from five patients
regarding ESR day 1 and DAS28-ESR day 1
MTX methotrexate, TNFi certolizumab-pegol, CTLA-4Ig abatacept, IL-6Ri tocilizumab, BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein
antibodies, CDAI clinical disease activity index, DAS28 disease activity score 28 joints, SJC-66 swollen joint count, 66 joints, TJC-68 tender joint count, 68 joints, CRP
C-reactive protein, ESR erythrocyte sedimentation rate, PGA patient global assessment
aMedian (range), Kruskal-Wallis followed by Dunn’s multiple comparison test
bn (%), Fisher’s exact test
cRetrospective patient-reported joint pain before RA diagnosis
Fig. 1 Elevated IFNα protein levels at baseline in early RA. IFNα protein
levels in plasma from patients with early RA before treatment initiation in
four treatment arms, methotrexate + prednisone, methotrexate + TNFi,
methotrexate + CTLA-4Ig, and methotrexate + IL-6Ri. The dotted line
denotes the cut-off for IFNα positivity (136 fg/mL). MTX (methotrexate),
TNFi (certolizumab-pegol), CTLA-4Ig (abatacept), and IL-6Ri (tocilizumab).
Kruskal-Wallis test followed by Dunn’s multiple comparison test
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Table 2 Demographic and clinical characteristics of IFNα-positive and IFNα-negative patients
N = 346 IFNα-negative (n = 255) IFNα-positivea (n = 91) p-value
Age, yearsb 58 (18–81) 58 (21–82) 0.53
Female sexc 170 (67%) 64 (70%) 0.60
BMI, kg/m2b 25 (18–43) 26 (19–43) 0.22
Current smokerc 46 (18%) 25 (27%) 0.07
Autoantibody statusc < 0.0001
RF-ACPA- 33 (13%) 3 (3%) p < 0.05d
RF+ACPA- 23 (9%) 2 (2%) ns
RF-ACPA+ 52 (20%) 2 (2%) p < 0.05d
RF+ACPA+ 146 (57%) 84 (92%) p < 0.05d
Disease activity day 1b
CDAI 27.8 (7.8–68.7) 28.6 (10.1–68.4) 0.13
DAS28-CRP 5.1 (2.2–8.3) 5.1 (3.3–7.7) 0.38
DAS28-ESR 5.5 (2.6–8.7) 5.5 (3.3–8.2) 0.43
SJC-66 11 (1–42) 11 (2–38) 0.68
TJC-68 13 (0–49) 16 (2–62) 0.16
CRP, mg/L 14 (0.3–216) 8 (0.5–190) 0.16
ESR, mm/h 28 (2–115) 28 (4–108) 0.26
PGA, mm 59 (2–100) 56 (22–100) 0.59
Disease activity week 24b
CDAI 3.4 (0–28.3) 3.5 (0–26.6) 0.47
DAS28-CRP 2.0 (1.1–4.8) 2.0 (1.0–5.0) 0.82
DAS28-ESR 2.3 (0–6.0) 2.2 (0–5.8) 0.91
SJC-66 0 (0–9) 0 (0–7) 0.88
TJC-68 1 (0–37) 2 (0–41) 0.22
CRP, mg/L 1 (0–39) 1 (0.1–15) 0.86
ESR, mm/h 8 (1–78) 8 (1–48) 0.52
PGA, mm 11 (0–78) 14 (0–92) 0.40
BMI body mass index, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, CDAI clinical disease activity index, DAS28 disease activity score 28 joints,
SJC-66 swollen joint count, 66 joints, TJC-68 tender joint count, 68 joints, CRP C-reactive protein, ESR erythrocyte sedimentation rate, PGA patient
global assessment
aIFNα positivity defined as IFNα protein level above 136 fg/mL
bMedian (range), Mann-Whitney U-test
cn (%), Fisher’s exact test
dp < 0.05 after post hoc step-down Bonferroni-Holm correction for multiple testing
Table 3 Factors associated with IFNα positivity at day 1 and week 24
OR for IFNα positivity at day 1a 95% CI OR for IFNα positivity at week 24a 95% CI
RF+ACPA+b 8.92 4.21–22.04 5.24 2.02–17.95
Current smokerb 1.70 0.91–3.15 2.18 1.01–4.56
CDAI day 1c 1.02 1.00–1.04 1.03 1.00–1.06
CRP day 1d 1.00 0.99–1.01 1.00 0.98–1.01
Multivariable logistic regression with IFNα positivity at day 1 and week 24 as the dependent variable. At day 1, IFNα-positive (n = 91) and IFNα-negative (n = 255).
At week 24, IFNα-positive (n = 41) and IFNα-negative (n = 305)
RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, CDAI clinical disease activity index
aIFNα positivity defined as IFNα protein level above 136 fg/mL
bYes versus no
cPer point increase
dPer 1 mg/L increase
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IFNα plasma protein levels decrease to a similar extent in
all treatment arms
Next, we investigated the effect of conventional and bio-
logic treatment strategies on IFNα protein levels. IFNα
protein levels decreased 24 weeks after treatment initi-
ation in all four treatment arms, and the absolute change
in IFNα protein level between day 1 and week 24 did
not differ between the treatment arms (Fig. 2A–E).
Baseline IFNα protein levels do not predict remission at
week 24
To evaluate IFNα protein in plasma as a biomarker for
remission in early RA, we compared baseline IFNα pro-
tein levels in patients who achieved CDAI remission at
week 24 versus those with low or moderate/high disease
activity. Baseline IFNα protein level did not differ ac-
cording to remission status in the whole group or in any
of the treatment arms (Fig. 3A–E). Similar results were
obtained when we compared patients who achieved
DAS28-ESR remission to those with low or moderate/
high disease activity (Additional Figure 2A-E).
To ensure that a potential association between IFNα
and remission status was not confounded by factors as-
sociated with IFNα, we added IFNα protein positivity,
current smoking, and double-positivity for RF and
ACPA to a logistic regression model. After adjustment
for current smoking and double-positivity, baseline IFNα
protein positivity was still not significantly associated
with CDAI (OR 0.79, 95% CI 0.47–1.32) or DAS28-ESR
(OR 0.64, 95% CI 0.37–1.09) remission at week 24. In
addition, in the 127 patients with IFNα levels above
LLOD, the baseline IFNα protein level did not correlate
with CDAI or DAS28-ESR at baseline, CDAI or DAS28-
ESR at week 24, or absolute change in CDAI or DAS28-
ESR from baseline until week 24 (Additional Figure 3).
Thus, the baseline protein level of IFNα did not predict
remission 24 weeks after treatment initiation in patients
with early RA.
Discussion
The expression of IRG is upregulated in a subgroup of
patients with RA, but IFNα protein levels have not previ-
ously been determined in RA. We demonstrate for the
first time that IFNα protein positivity is present in a sub-
group of patients with untreated early RA. IFNα protein
positivity was strongly associated with double-positivity
for RF and ACPA but not with disease activity. Treat-
ment with both conventional and biologic DMARDs led
to decreased levels of IFNα protein, but the absolute
change did not differ between the treatment arms. Pre-
treatment levels of IFNα protein did not predict remis-
sion at week 24.
Previously, gene variants of interferon regulatory
factor-5 (IRF-5) were shown to be associated with
seronegative RA [26, 27], leading to the notion that the
type I IFN pathway may be more important in
autoantibody-negative patients. Here, we show that
double-positivity for RF and ACPA is associated with in-
creased risk for IFNα protein positivity, while single-
positivity and double-negativity are related to IFNα
negativity. One explanation could be that RF and ACPA
in combination might induce a more potent stimulation
of IFNα protein production. Indeed, double-positive pa-
tients with RA exhibit higher levels of the proinflamma-
tory cytokines TNF, IL-6, and IL-1β than single-positive
patients [28]. However, it is also possible that IFNα can
induce the production of RF and ACPA. IFNα stimulates
B cell activating factor [29, 30], plasma cell differenti-
ation, and antibody secretion [31]. Thus, IFNα may
stimulate RF and ACPA autoantibody production, which
form immune complexes that may in turn stimulate
plasmacytoid dendritic cells to produce IFNα protein.
The cut-off for IFNα positivity was 136 fg/mL, based
on 3 SD above mean level for 68 healthy blood donors
[21]. We obtained similar results when using LLOD as
the cut-off. When we measured IFNα protein in 27
healthy controls, all had values below LLOD. Using the
same cut-off, 52% of patients with SLE were IFNα-
positive [21] compared to 26% of early RA patients in
the present study. This is in line with previous results,
where lower IRG expression has been seen in RA com-
pared to SLE [9, 32]. Nucleic acids stimulate IFNα pro-
tein production from plasmacytoid dendritic cells, and
elevated IFNα protein levels in SLE are associated with
the presence of autoantibodies against DNA, ribonucleo-
protein, and the RNA-binding Smith antigen [21]. Thus,
an explanation for the larger proportion of IFNα-
positive patients in SLE relative to RA may be that auto-
antibodies in SLE target endogenous nucleic acids that
may be more potent than RF and ACPA in stimulating
IFNα protein production. Besides the presence of auto-
antibodies, SLE and RA share several pathological fea-
tures including joint pain, fatigue, and a female
predisposition, and the diseases may overlap. Therefore,
the shared overexpression of IFNα in subgroups of pa-
tients with SLE and RA may contribute to the similar-
ities between the diseases. Since the IFNα/β receptor
inhibitor anifrolumab suggested improvements to pri-
mary or secondary outcomes in SLE [33, 34], it will be
interesting to see whether RA patients with high IFNα
protein level may benefit from this medication.
Increased IRG expression is evident in early and estab-
lished RA. Although the definition varies, elevated IRG
expression was described in 42–61% of patients with
early RA [10, 11] and 21–57% of patients with estab-
lished RA [9, 11, 12, 35–37]. While its effect on remis-
sion is unknown, IRG expression has been associated
with disease activity in early RA. Elevated baseline IRG
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expression associated with increased DAS28 6 months
after treatment initiation with MTX and glucocorticoid
[5] as well as MTX, intramuscular glucocorticoid, and/or
hydroxychloroquine [11]. However, another study found
no association to disease activity 6 months after treat-
ment initiation with MTX, prednisolone, and/or
sulfasalazine [38]. In the present study, IFNα protein
positivity was not related to disease activity or remission
6 months after initiation of conventional or biologic
treatment.
IRG expression has been suggested as a predictive bio-
marker for the response to biologic therapies. High or
Fig. 2 IFNα protein levels are reduced after treatment initiation with conventional and biologic treatment strategies. IFNα protein levels in plasma
from patients with early RA before (d1) and 24 weeks after treatment initiation (w24) with A methotrexate + prednisone (n = 85), B methotrexate
+ TNFi (n = 87), C methotrexate + CTLA-4Ig (n = 91), and D methotrexate + IL-6Ri (n = 82). Wilcoxon matched-pairs signed rank test. E Absolute
difference in IFNα plasma protein levels between week 24 and day 1 in four treatment arms. MTX (methotrexate), TNFi (certolizumab-pegol),
CTLA-4Ig (abatacept), and IL-6Ri (tocilizumab). Kruskal-Wallis test followed by Dunn’s multiple comparison test
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increasing IRG expression associated with poor response
to anti-TNF treatment [12, 13] although one study re-
ported association with good response [14] and one saw
no association [6]. Whether IRG expression predicts re-
sponse to CTLA-4Ig has not been studied, but high IRG
expression was also suggested to predict a good response
to anti-IL-6Ri treatment [15]. On a protein level, how-
ever, we found that IFNα protein levels decreased irre-
spective of treatment, and the baseline IFNα protein
level did not differ according to remission status in any
of the treatment arms. The B-cell depleting agent rituxi-
mab was not included as one of the treatment arms,
since it is not recommended as the first biological treat-
ment in RA by Swedish or European guidelines. Given
the association to autoantibody positivity, it would be of
interest to evaluate IFNα protein as a biomarker for
treatment effect by rituximab. Indeed, low pre-treatment
IRG expression was shown to predict good response to
rituximab [16–19]. IFNα stimulates B cell survival, and
the repopulation of depleted B-cells may be accelerated
Fig. 3 Baseline IFNα protein levels do not predict remission after treatment. Baseline IFNα protein levels in plasma from patients with early RA,
stratified according to CDAI 24 weeks after treatment initiation; in remission (CDAI 0–2.8), low disease activity (CDAI 2.9–10.0), and moderate/high
disease activity (CDAI 10.1–76.0) with A all treatments, B methotrexate + prednisone, C methotrexate + TNFi, D methotrexate + CTLA-4Ig, and E
methotrexate + IL-6Ri. MTX (methotrexate), TNFi (certolizumab-pegol), CTLA-4Ig (abatacept), IL-6Ri (tocilizumab). Kruskal-Wallis test followed by
Dunn’s multiple comparison test
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in patients with high IRG expression. In addition, since
IFNα exerts its effect through the JAK-STAT pathway, it
is relevant to examine whether IFNα protein level may
predict treatment effect to JAK inhibitors in early RA.
This study uses data and plasma samples from the
investigator-initiated NORD-STAR study in early un-
treated RA, and the clinical trial design with
randomization to four different treatment arms is a
major strength. In addition, previous studies have used
proxy markers such as IRG expression to evaluate the
role of IFNα in RA, while we were able to sensitively
measure the levels of IFNα protein in plasma. However,
one limitation is that we do not have data for both IRG
expression and IFNα plasma levels. Further, the titers of
RF and ACPA were measured at different laboratories,
which precludes the analysis of autoantibody levels in re-
lation to IFNα protein levels.
Conclusions
In conclusion, IFNα protein positivity was present in a
subgroup of patients with early untreated RA and associ-
ated with double-positivity for RF and ACPA, but not
with disease activity, and did not predict remission 24
weeks after treatment initiation. The association between
IFNα and double-positivity for autoantibodies warrants
further investigation regarding the role of IFNα in the
pathogenesis of early RA. For example, measurement of
IFNα protein in synovial fluid would be of value to eluci-
date the role of IFNα in the local inflammation of the
joint.
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